Semaglutide could benefit millions of Americans with obesity, heart disease

Semaglutide (brand name: Wegovy) has the potential to markedly reduce the risk of heart attacks and other heart-related conditions among millions of Americans with obesity who have also been diagnosed with cardiovascular disease, a Yale study shows.

Leave a Reply

Your email address will not be published.